| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/394057/2013 (28.06.13) |
| Publication Date | 28/06/2013 |
| Content Type | News |
|
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), in June 2013, recommended granting a marketing authorisation for a new advanced-therapy medicinal product (ATMP). Provenge is recommended for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated. |
|
| Source Link | Link to Main Source http://www.emea.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001835.jsp&mid=WC0b01ac058004d5c1 |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
